A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)

Trial Profile

A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Proof-of-Concept Study of Brimonidine Eye Drops for the Treatment of Dry Eye Disease (DED)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Mar 2018

At a glance

  • Drugs Brimonidine (Primary) ; Loteprednol etabonate (Primary)
  • Indications Dry eyes
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Ocugen
  • Most Recent Events

    • 20 Mar 2018 According to an Ocugen media release, this study met its primary endpoint of tolerability over a 12-week period.
    • 20 Mar 2018 According to an Ocugen media release, the company look forward to present the full results at a future academic meeting, and discussing with the FDA in the coming months.
    • 20 Mar 2018 Positive results of this trial, presented in an Ocugen media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top